Used in pharmaceutical research as a potent and selective inhibitor of cyclin-dependent kinases (CDKs), particularly CDK7 and CDK9, which play key roles in cell cycle regulation and transcription. This compound shows promise in oncology for targeting cancer cells by disrupting transcriptional processes in tumors, especially those dependent on dysregulated gene expression. It is being investigated for its antitumor activity in hematological malignancies and solid tumors. Its ability to induce apoptosis and suppress tumor growth in preclinical models makes it a candidate for development in targeted cancer therapies.